These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 20819019)

  • 1. TRAIL receptor signaling and therapeutics.
    Abdulghani J; El-Deiry WS
    Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF-related apoptosis-inducing ligand: signalling of a 'smart' molecule.
    Manzo F; Nebbioso A; Miceli M; Conte M; De Bellis F; Carafa V; Franci G; Tambaro FP; Altucci L
    Int J Biochem Cell Biol; 2009 Mar; 41(3):460-6. PubMed ID: 18243765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting of CD95 and the TRAIL death receptors.
    Gerspach J; Pfizenmaier K; Wajant H
    Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):294-310. PubMed ID: 21762072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
    Wang S
    Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAIL/TRAIL-R in hematologic malignancies.
    Testa U
    J Cell Biochem; 2010 May; 110(1):21-34. PubMed ID: 20336667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
    Cretney E; Takeda K; Smyth MJ
    Int J Biochem Cell Biol; 2007; 39(2):280-6. PubMed ID: 17097329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer.
    Martinez-Lostao L; Marzo I; Anel A; Naval J
    Biochem Pharmacol; 2012 Jun; 83(11):1475-83. PubMed ID: 22230480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting death-receptors in radiation therapy.
    Niemöller O; Belka C
    Results Probl Cell Differ; 2009; 49():219-39. PubMed ID: 19582410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
    Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
    Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.
    Wajant H; Moosmayer D; Wüest T; Bartke T; Gerlach E; Schönherr U; Peters N; Scheurich P; Pfizenmaier K
    Oncogene; 2001 Jul; 20(30):4101-6. PubMed ID: 11494138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
    Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
    J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
    Rowinsky EK
    J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRAIL as a target in anti-cancer therapy.
    Wu GS
    Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
    Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of elevated pressure in TRAIL-induced apoptosis in human lung carcinoma cells.
    Oh S; Kwon D; Lee HJ; Kim J; Lee E
    Apoptosis; 2010 Dec; 15(12):1517-28. PubMed ID: 20623193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TRAIL apoptotic pathway in cancer onset, progression and therapy.
    Johnstone RW; Frew AJ; Smyth MJ
    Nat Rev Cancer; 2008 Oct; 8(10):782-98. PubMed ID: 18813321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
    Smith MR; Jin F; Joshi I
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis.
    Peuhu E; Rivero-Müller A; Stykki H; Torvaldson E; Holmbom T; Eklund P; Unkila M; Sjöholm R; Eriksson JE
    Oncogene; 2010 Feb; 29(6):898-908. PubMed ID: 19935713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway.
    Vondálová Blanárová O; Jelínková I; Szöor A; Skender B; Soucek K; Horváth V; Vaculová A; Andera L; Sova P; Szöllosi J; Hofmanová J; Vereb G; Kozubík A
    Carcinogenesis; 2011 Jan; 32(1):42-51. PubMed ID: 21037225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
    Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
    Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.